Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800 near-infrared imaging during minimally invasive surgery for lung cancer
2021-006454-30Phase 2Completed
- Sponsor
- University of Turin
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab-IRDye 800CW in non-small cell lung cancer (NSCLC) and lung neoplasm, sponsored by University of Turin. Primary endpoint: Detection of lung nodule during surgery by NIR camera. Started May 2022; status: completed.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
non-small cell lung cancer (NSCLC)lung neoplasm
Beyond the preview
Go deeper on 2021-006454-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006454-30.